Table 2.2.
Vaccines presently under clinical trials.
| NCT number | Interventions | Phases | Enrollment | Participating country |
|---|---|---|---|---|
| NCT04299724 | Pathogen-specific aAPC | Phase 1 | 100 | China |
| NCT04276896 | Injection and infusion of LV-SMENP-DC vaccine and antigen-specific cytotoxic T lymphocytes | Phase 1/phase 2 | 100 | China |
| NCT04313127 | Recombinant vaccine using adenovirus type 5 vector | Phase 1 | 108 | China |
| NCT04341389 | Recombinant vaccine using adenovirus type 5 vector | Phase 2 | 500 | China |
| NCT04334980 | BacTRL-spike | Phase 1 | 84 | Canada |
| NCT04324606 | ChAdOx1 nCoV-19 MenACWY placebo | Phase 1/phase 2 | 510 | England |
| NCT04283461 | Biological: mRNA-1273 | Phase 1 | 45 | United States of America |
| NCT04336410 | INO-4800 device: CELLECTRAÂ 2000 | Phase 1 | 40 | United States of America |
| NCT04368988 | SARS-CoV-2 rS spike protein nanoparticle vaccine with/without adjuvant | Phase 1/phase 2 | 131 | Australia |
| NCT04380532 | Tableted V-SARS vaccine | Phase 1 | 20 | Canada |
| NCT04368728 | BNT162a1 (viral infection) BNT162b1 (respiratory viral diseases) BNT162b2 (viral infection) BNT162c2 (adverse reaction) |
Phase 1/phase 2 | 7600 | United States Germany |
| NCT04276896 | Lentiviral vector system (NHP/TYF) to modify and activate dendritic cells and T cells | Phase 1/phase 2 | 100 | China |
| NCT04357028 | Measles, mumps, and rubella vaccine | Phase 3 | 200 | Egypt |